The U.S. Food and Drug Administration has approved Foundayo (orforglipron) with required postmarketing studies, including pediatric trials, pregnancy registries, and long-term safety monitoring for cancer and liver risks.
Written By: Vikas Londhe, Chief Editor
The U.S. Food and Drug Administration has approved Foundayo (orforglipron) for chronic weight management in adults with obesity or overweight with at least one weight‑related comorbidity, as stated in its approval letter to Eli Lilly and Company. The approval is accompanied by multiple required postmarketing studies and clinical trials to further evaluate the drug’s safety profile in specific populations and for identified risks.
Pediatric study requirements and deferrals
Under the Pediatric Research Equity Act, the FDA waived pediatric study requirements for children under 6 years of age, citing limited therapeutic benefit and low expected use in this population. Pediatric studies in patients aged 6 to 17 years have been deferred and are required postmarketing.
These include an ongoing 72‑week randomized, placebo‑controlled trial in adolescents aged 12 to less than 18 years and a planned 84‑week study in children aged 6 to less than 12 years. Both studies are designed to evaluate the safety, efficacy, and pharmacokinetics of orforglipron as an adjunct to lifestyle intervention.
Required registries for pediatric, pregnancy, and cancer safety
The FDA has determined that routine postmarketing adverse event reporting will not be sufficient to characterize certain serious risks and has therefore required the establishment of multiple long‑term registries.
A disease‑based pediatric registry will follow patients aged 6 years and older for at least 10 years to assess growth, development, and adverse events, including fractures and malnutrition.
A prospective pregnancy exposure registry will collect data on maternal, fetal, and infant outcomes, including congenital malformations, pregnancy complications, and postnatal development.
In addition, a separate pregnancy study using an alternative design (for example, claims or electronic medical record data) is required to compare outcomes between orforglipron‑exposed and unexposed populations.
The FDA has also required a medullary thyroid carcinoma registry‑based case series of at least 15 years’ duration to systematically monitor the annual incidence of this cancer in the United States and to assess any potential association with orforglipron use. The registry will capture detailed medical histories of incident cases, including prior exposure to the drug.
Additional clinical trials and pharmacovigilance requirements
The approval letter requires completion of ongoing and new clinical trials to assess specific safety risks, including: evaluation of major adverse cardiovascular events and drug‑induced liver injury; assessment of delayed gastric emptying and aspiration risk; and a lactation study to measure drug concentrations in breast milk.
The FDA has requested enhanced pharmacovigilance for drug‑induced liver injury for five years following approval, including expedited reporting of serious cases and periodic cumulative safety analyses. The agency also requires periodic reporting on the status of all postmarketing studies and clinical trials, with timelines for protocol submission, study completion, and final report submission specified in the approval letter.
Approval timeline and availability
Foundayo (orforglipron) was approved by the FDA on April 1, 2026, following submission of the new drug application in January 2026. The drug was subsequently commercialized in the United States on April 9, 2026, making it available for clinical use as a pharmacological option for long‑term weight management in adults.
References
FOUNDAYO NDA APPROVAL, POSTMARKETING REQUIREMENTS UNDER 505(o) https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf
About the Writer
Vikas Londhe is the Chief Editor and a subject matter expert in patient safety and drug safety. He has a deep understanding of pharmacology, medication-related risks, patient and drug-related errors, and global drug regulatory frameworks. Through his work, he focuses on translating complex medical and regulatory information into clear, evidence-based insights that support safer medication use and informed healthcare decisions.
